Clinical Trial Update: Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 trial evaluating darunavir/ritonavir for HIV postexposure prophylaxis, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• darunavir/ritonavir (darunavir/ritonavir)

Snippet

Sponsor: Janssen-Cilag G.m.b.H | Conditions: Human Immunodeficiency Virus (HIV) | Phase 3 | Status: COMPLETED | Results posted: 2016-10-11